Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial.

20/11/2024

HemaSphere

Authors: Elias K Mai, Axel Nogai, Henk M Lokhorst, Bronno van der Holt, Sonja Zweegman, Katja C Weisel, Sandra Croockewit, Anna Jauch, Jens Hillengass, Marian Stevens-Kroef, Marc S Raab, Annemiek Broijl, Gerard M J Bos, Peter Brossart, Paula Ypma, Christine Hanoun, Uta Bertsch, Thomas Hielscher, Hans J Salwender, Christoph Scheid, Hartmut Goldschmidt, Pieter Sonneveld